See more : Tigi Ltd. (TIGI.TA) Income Statement Analysis – Financial Results
Complete financial analysis of OncoSec Medical Incorporated (ONCS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of OncoSec Medical Incorporated, a leading company in the Biotechnology industry within the Healthcare sector.
- Miton UK MicroCap Trust plc (MINI.L) Income Statement Analysis – Financial Results
- Hunt Companies Acquisition Corp. I (HTAQ-UN) Income Statement Analysis – Financial Results
- MobileSmith, Inc. (MOSTQ) Income Statement Analysis – Financial Results
- Trump Media & Technology Group Corp. (DJTWW) Income Statement Analysis – Financial Results
- Hind Aluminium Industries Limited (HINDALUMI.BO) Income Statement Analysis – Financial Results
OncoSec Medical Incorporated (ONCS)
About OncoSec Medical Incorporated
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in clinical trials collaboration and supply agreement (KEYNOTE-695) and metastatic triple negative breast cancer, which is in Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, the company is developing monotherapy biomarker study in patients with advanced or metastatic TNBC that has completed the Phase II clinical trials; and technology to treat liver, lung, bladder, pancreatic, and other visceral lesions. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and enhanced IL-12 DNA-plasmid; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. The company was incorporated in 2008 and is headquartered in Pennington, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 25.82M | 34.10M | 25.10M | 18.45M | 17.42M | 11.95M | 14.74M | 13.13M | 5.80M | 3.16M | 2.37M | 648.31K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 11.19M | 14.28M | 18.31M | 11.97M | 18.69M | 9.50M | 12.14M | 8.11M | 6.15M | 3.91M | 3.16M | 1.05M | 27.16K | 33.71K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.19M | 14.28M | 18.31M | 11.97M | 18.69M | 9.50M | 12.14M | 8.11M | 6.15M | 3.91M | 3.16M | 1.05M | 27.16K | 33.71K | 7.19K |
| Other Expenses | 28.86K | -704.00 | 185.05K | 440.04K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 37.01M | 48.38M | 43.41M | 30.42M | 36.11M | 21.45M | 26.89M | 21.24M | 11.95M | 7.06M | 5.53M | 1.70M | 27.16K | 33.71K | 7.19K |
| Cost & Expenses | 37.01M | 48.38M | 43.41M | 30.42M | 36.11M | 21.45M | 26.89M | 21.24M | 11.95M | 7.06M | 5.53M | 1.70M | 27.16K | 33.71K | 7.19K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 20.93K | 15.86K | 5.11K | 3.81K | 6.37M | 0.00 | 0.00 | 0.00 | 20.68K | 83.22K | -3.16M | 1.36K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.10M | 1.08M | 1.18M | 683.75K | 3.67M | 379.99K | 355.58K | 664.60K | 780.11K | 736.88K | 717.45K | 250.82K | -9.00K | 0.00 | 0.00 |
| EBITDA | -35.92M | -47.30M | -42.23M | -29.73M | -32.43M | -21.07M | -26,886.05B | -21.24B | -11.95B | -7.06B | -4.81M | -1.70B | -36.16K | -33.71K | -7.19K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -37.01M | -48.38M | -43.41M | -30.42M | -36.11M | -21.45M | -26.89M | -21.24M | -11.95M | -7.06M | -5.53M | -1.70M | -27.16K | -33.71K | -7.19K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -501.72K | 800.14K | 283.07K | 141.92K | -3.03M | 0.00 | 0.00 | 0.00 | -20.68K | -83.22K | 3.16M | -2.06M | 9.00K | 0.00 | 0.00 |
| Income Before Tax | -37.51M | -47.58M | -43.13M | -30.27M | -39.14M | -21.45M | -26.89M | -21.24M | -11.97M | -7.15M | -2.36M | -3.76M | -18.16K | -33.71K | -7.19K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -3.33M | -2.41M | -872.59K | 1.30K | 680.00 | 1.39K | 2.46K | 1.97K | 41.77K | 2.00K | 2.40K | 1.60K | 9.00K | 0.00 | 0.00 |
| Net Income | -34.18M | -45.17M | -42.25M | -30.28M | -39.14M | -21.45M | -26.89M | -21.24M | -12.01M | -7.15M | -2.36M | -3.76M | -27.16K | -33.71K | -7.19K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -19.13 | -30.20 | -56.22 | -94.43 | -214.59 | -233.73 | -358.20 | -367.73 | -277.38 | -295.25 | -154.28 | -261.28 | -1.75 | -2.17 | -0.46 |
| EPS Diluted | -19.13 | -30.20 | -56.22 | -94.43 | -214.59 | -233.73 | -358.20 | -367.73 | -277.38 | -295.25 | -154.28 | -261.28 | -1.75 | -2.17 | -0.46 |
| Weighted Avg Shares Out | 1.79M | 1.50M | 751.57K | 320.60K | 182.38K | 91.77K | 75.07K | 57.77K | 43.31K | 24.22K | 15.33K | 14.39K | 15.56K | 15.56K | 15.56K |
| Weighted Avg Shares Out (Dil) | 1.79M | 1.50M | 751.57K | 320.60K | 182.38K | 91.77K | 75.07K | 57.77K | 43.31K | 24.22K | 15.33K | 14.39K | 15.56K | 15.56K | 15.56K |
Why Is OncoSec Medical (ONCS) Stock Up 100% Today?
Why Is OncoSec Medical (ONCS) Stock Down 48% Today?
3 Top Penny Stocks To Watch After Big News This Week
Avoid Common Penny Stocks Trading Mistakes With These Tips
ONCS Stock: Over 120% Surge Explantion
Why is OncoSec Medical (ONCS) Stock Up 91% Today?
Why Is OncoSec Medical (ONCS) Stock Down 25% Today?
Top 5 most-shorted stocks as of December 2022
ONCS Stock Alert: What to Know About OncoSec Medical as It Drops Today
OncoSec Announces Pipeline Prioritization and Workforce Reduction
Source: https://incomestatements.info
Category: Stock Reports